Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients

被引：0
|
作者：
Maertens, Johan A. [1 ]
Cordonnier, Catherine [2 ,3 ]
Jaksch, Peter [4 ]
Poire, Xavier [5 ]
Wu, Jingyang J. [6 ]
Wijatyk, Anna [6 ]
Saliba, Faouzi [7 ]
Witzke, Oliver [8 ]
Villano, Stephen [9 ]
机构：
[1] Univ Ziekenhuizen, Leuven, Belgium
[2] Henri Mondor Hosp, Creteil, France
[3] Univ Paris Est Creteil, Creteil, France
[4] Med Univ Vienna, Gen Hosp, Vienna, Austria
[5] Clin Univ St Luc, Brussels, Belgium
[6] Shire, Lexington, MA USA
[7] Hop Paul Brousse, AP HP, Villejuif, France
[8] Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany
[9] Shire, Wayne, PA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2017年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
229
引用
收藏
页码：S180 / S181
页数：2
相关论文
共 43 条
  • [1] Maribavir versus valganciclovir for pre-emptive treatment of cytomegalovirus viraemia: a randomized, dose-ranging, phase 2 study among haematopoietic stem cell transplant and solid organ transplant recipients
    Maertens, J.
    Cordonnier, C.
    Jaksch, P.
    Poire, X.
    Wu, J.
    Wijatyk, A.
    Saliba, F.
    Faouzi
    Witzke, O.
    Villano, S.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S100 - S102
  • [2] Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
    Papanicolaou, Genovefa A.
    Silveira, Fernanda P.
    Langston, Amelia A.
    Pereira, Marcus R.
    Avery, Robin K.
    Wijatyk, Anna
    Wu, Jingyang J.
    Boeckh, Michael J.
    Marty, Francisco M.
    Villano, Stephen
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S51 - S52
  • [3] Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients
    Strippoli, GFM
    Hodson, EM
    Jones, C
    Craig, JC
    TRANSPLANTATION, 2006, 81 (02) : 139 - 145
  • [4] Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
    Papanicolaou, Genovefa A.
    Silveira, Fernanda P.
    Langston, Amelia A.
    Pereira, Marcus R.
    Avery, Robin K.
    Uknis, Marc
    Wijatyk, Anna
    Wu, Jingyang
    Boeckh, Michael
    Marty, Francisco M.
    Villano, Stephen
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (08) : 1255 - 1264
  • [5] Cytomegalovirus Retinitis in a Hematopoietic Stem Cell Transplant Recipient During Maribavir Pre-emptive Therapy
    Jang, Hyeon Mu
    Park, Han-Seung
    Sung, Heungsup
    Kim, Sung-Han
    INFECTION AND CHEMOTHERAPY, 2025, 57 (01): : 168 - 171
  • [6] Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients
    Ruiz-Camps, Isabel
    Len, Oscar
    de la Camara, Rafael
    Gurgui, Mercedes
    Martino, Rodrigo
    Jarque, Isidro
    Barrenetxea, Cristina
    Diaz de Heredia, Cristina
    Batlle, Montserrat
    Rovira, Montserrat
    de la Torre, Julian
    Torres, Antonio
    Aguilar, Manuela
    Espigado, Ildefonso
    Martin-Davila, Pilar
    Bou, German
    Borrell, Nuria
    Maria Aguado, Jose
    Pahissa, Albert
    ANTIVIRAL THERAPY, 2011, 16 (07) : 951 - 957
  • [7] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
    Ladhani, Maleeka
    NEPHROLOGY, 2013, 18 (03) : 235 - 236
  • [8] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
    Owers, Daniel S.
    Webster, Angela C.
    Strippoli, Giovanni F. M.
    Kable, Kathy
    Hodson, Elisabeth M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [9] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
    Strippoli, GF
    Hodson, EM
    Jones, CJ
    Craig, JC
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [10] ORAL VALGANCICLOVIR IS EFFECTIVE AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
    Atay, D.
    Erbey, F.
    Akcay, A.
    Dag, A.
    Ozturk, G.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S460 - S460
12345